Comprehensive insight into human aminoacyl-tRNA synthetases as autoantigens in idiopathic inflammatory myopathies

Critical Reviews in Immunology

Volumn 27, Issue 6, 2007, Pages 559-572

  Jura, Miroslawa ^a,b   Rychlewski, Leszek ^b   Barciszewski, Jan ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b BIOINFOBANK INSTITUTE   (Poland)

Author keywords

Anti Jo 1; Anti PL 12; Anti PL 7; Autoantibodies; Idiopathic inflammatory myopathy

Indexed keywords

ALANINE TRANSFER RNA; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CHEMOATTRACTANT; JO 1 ANTIBODY; THREONINE TRANSFER RNA;

CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENETIC RISK; HUMAN; IDIOPATHIC DISEASE; IMMUNOGENETICS; IMMUNOPATHOGENESIS; MYOSITIS; PRIORITY JOURNAL; REVIEW;

EID: 38049067488     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v27.i6.60     Document Type: Review

References (83)

1. Briemberg HR, Amato AA. Dermatomyositis and polymyositis. Curr Treat Options Neurol. 2003;5:349-56.
2. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase immune responses: Insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2003;15:708-13.
3. Targoff IN, Reichlin M. Humoral immunity in polymyositis and dermatomyositis. Mt Sinai J Med. 1988;55:487-93.
4. Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity. 2005;38:73-8.
5. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781-91.
6. Szymanski M, Deniziak M, Barciszewski J. The new aspects of aminoacyl-tRNA synthetases. Acta Biochim Pol. 2000;47:821-34.
7. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol. 1990;144:1737-43.
8. Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999;162:2315-20.
9. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity. Nature. 1983;30:177-9.
10. Freist W, Verhey JF, Ruhlmann A, Gauss DH, Arnez JG. Histidyl-tRNA synthetase. Biol Chem. 1999;380:623-46.
11. Arnez JG, Moras D. Structural and functional considerations of the aminoacylation reaction. Trends Biochem Sci. 1997;22:211-6.
12. Arnez JG, Augustine JG, Moras D, Francklyn CS. The first step of aminoacylation at the atomic level in histidyl-tRNA synthetase. Proc Natl Acad Sci USA. 1997;94:7144-9.
13. Arnez JG, Flanagan K, Moras D, Simonson T. Engineering and Mg2+ site to replace a structurally conserved arginine in the catalytic center of histidyl-tRNA synthetase by computer experiments. Proteins. 1998;32:362-80.
14. O'Hanlon TP, Raben N, Miller FW. A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HisRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. Biochem Biophys Res Commun. 1995;210:556-66.
15. Francin M, Kaminska M, Kerjan P, Mirande M. The N-terminal domain of mammalian Lysyl-tRNA synthetase is a functional tRNA-binding domain. J Biol Chem. 2002;277:1762-9.
16. Francin M, Mirande M. Functional dissection of the eukaryotic-specific tRNA-interacting factor of lysyl-tRNA synthetase. J Biol Chem. 2003;278:1472-9.
17. Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA. 1990;87:9933-7.
18. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest. 1990;85:468-75.
19. Wasicek CA, Reichlin M, Montes M, Raghu G. Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med. 1984;76:538-44.
20. Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science. 1991;252:1162-4.
21. Raben N, Nichols R, Dohlman J, McPhie P, Sridhar V, Hyde C, Leff R, Plotz P. A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. J Biol Chem. 1994;269:24277-83.
22. Dohlman JG, Lupas A, Carson M. Long charge-rich alpha-helices in systemic autoantigens. Biochem Biophys Res Commun. 1993;195:686-96.
23. Beaulande M, Kron M, Hirakata M, Hartlein M. Human anti-asparaginyl-tRNA synthetase autoantibodies (anti-KS) increase the affinity of the enzyme for its tRNA substrate. FEBS Lett 2001;494:170-4. Erratum in FEBS Lett. 2001;508:493.
24. Ramsden DA, Chen J, Miller FW, Misener V, Bernstein RM, Siminovitch KA, et al. Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response. J Immunol. 1989;143:2267-72.
25. Tsui FW, Bernstein RM, Mathews MB, Miller FW. Mapping the epitopes on Jo-1 (histidyl-tRNA synthetase). Prog Leukocyte Biol. 1989;9:473-6.
26. Kaminska M, Shalak V, Mirande M. The appended C-domain of human methionyl-tRNA synthetase has a tRNA-sequestering function. Biochemistry. 2001;40:14309-16.
27. Martin A, Shulman MJ, Tsui FW. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J. 1995;9:1226-33. Erratum in FASEB J. 1995;9:1496.
28. Pearce DC, Yount WJ, Eisenberg RA. Subclass restriction of anti-SS-B (La) autoantibodies. Clin Immunol Immunopathol.1986;38:111-9.
29. Lieu TS, Reimer CB, Sontheimer RD. Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response. J Invest Dermatol. 1988;90:158-64.
30. His autoantibodies that recognize conformational epitope in sera of. patients with myositis. Arthritis Rheum. 1998;41:1428-37.
31. Fahoum SK, Yang DC. Purification of mammalian histidyl-tRNA synthetase and its interaction with myositis-specific anti-Jo-1 antibodies. Biochemistry. 1987;26:5871-7.
32. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992;35:449-56.
33. Blechynden LM, Lawson CM, Garlepp MJ. Sequence and polymorphism analysis of the murine gene encoding histidyl-tRNA synthetase. Gene. 1996;178:151-6.
34. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmunity. 1999;12:137-42.
35. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: Clinical, genetic and diagnostic insights. Autoimmunity Reviews. 2007;6:432-7.
36. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990;88:241-51.
37. Ala coexist and are associated with myositis. J Exp Med. 1986;163:1281-91.
38. Bunn CC, Mathews MB. Autoreactive epitope defined as the anticodon region of alanine transfer RNA. Science. 1987;238:1116-9.
39. Bunn CC, Mathews MB. Two human tRNA(Ala) families are recognized by autoantibodies in polymyositis sera. Mol Biol Med. 1987;4:21-36.
40. Becker HF, Corda Y, Mathews MB, Fourrey JL, Grosjean H. Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies. RNA. 1999;5:865-75.
41. Bjork GR. Modified nucleosides at position 34 and 37 of tRNAs and their predicted coding capacities. In: Grosjean H, Benne R, editors. Modification and editing of RNA. Washington, DC: ASM; 1998. p. 577-81.
42. Brouwer R, Vree Egberts W, Jongen PH, van Engelen BG, van Venrooij WJ. Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis Rheum. 1998;41:1428-37.
43. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12:475-81.
44. Garcia-Lozano JR, Gonzalez-Escribano MF, Rodriguez R, Rodriguez-Sanchez JL, Targoff IN, Wichmann I, et al. Detection of anti-PL-12 autoantibodies by ELISA using a recombinant antigen; study of the immunoreactive region. Clin Exp Immunol. 1998;114:161-5.
45. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest.1993;91:2556-64.
46. Ge Q, Weu EP, Targoff IN. Primary structure and functional expression of human glycyl-tRNA synthetase, an autoantigen in myositis. J Biol Chem. 1994;269:28790-7.
47. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992;35:821-30.
48. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: Current hypotheses. Curr Rheumatol Rep. 2003;5:425-30.
49. Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol. 1999;92:161-9.
50. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101:746-54.
51. Bartoli C, Civatte M, Pellissier JF, Figarella-Branger D. CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies. Acta Neuropathol (Berl). 2001;102:385-92.
52. Blechynden LM, Lawson CM, Garlepp MJ. Sequence and polymorphism analysis of the murine gene encoding histidyl-tRNA synthetase. Gene. 1996;178:151-6.
53. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999;284:147-51.
54. Martinis SA, Plateau P, Cavarelli J, Florentz C. Aminoacyl-tRNA synthetases: A new image for a classical family. Biochimie. 1999;81:683-700.
55. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem. 1992;267:20239-47.
56. Kao J, Fan YG, Haehnel I, Brett J, Greenberg S, Clauss M, et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response. J Biol Chem. 1994;269:9774-82.
57. Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, et al. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. J Biol Chem. 1994;269:25106-19.
58. Shalak V, Kaminska M, Mitnacht-Kraus R, Vandenabeele P, Clauss M, Mirande M. The EMAPII cytokine is released from the mammalian multisynthetase complex after cleavage of its p43/proEMAPII component. J Biol Chem. 2001;276:23769-76.
59. Park H, Park, SG, Kim J, Ko YG, Kim S. Signalling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. Cytokine. 2002;20:148-53.
60. Sang Lee J, Gyu Park S, Park H, Seol W, Lee S, Kim S. Interaction network of human aminoacyl-tRNA synthetases and subunits of elongation factor 1 complex. Biochem Biophys Res Commun. 2002;291:158-64.
61. Andrade F, Roy S, Nicholson D, Th ornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity. 1998;8:451-60.
62. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J Exp Med. 1999;190:815-26.
63. Walker E.J, Jeffrey PD. Polymyositis and molecular mimicry, a mechanism of autoimmunity. Lancet. 1986;2:605-7.
64. Blaszczyk M, Dziubek Z, Jablonska S, Olszynska M. A probable role of an infectious agent in polymyositis associated with antibodies against histidyl-tRNA synthetase: Antisynthetase syndrome. J Eur Acad Dermatol Venereol. 1998;10:278-80.
65. Goldstein R, Duvic M, Targoff IN, Reichlin M, McMenemy AM, Reveille JD, et al. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum. 1990;33:1240-8.
66. Archard LC, Richardson PJ, Olsen EG, Dubowitz V, Sewry C, Bowles NE. The role of Coxsackie B viruses in the pathogenesis of myocarditis, dilated cardiomyopathy and inflammatory muscle disease. Biochem Soc Symp. 1987;53:51-62.
67. Salemi S, Caporossi AP, Boff a L, Longobardi MG, Barnaba V. HIVgp120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J Exp Med. 1995;181:2253-7.
68. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine. 2006;85:111-27.
69. De Wall SL, Painter C, Stone JD, Bandaranayake R, Wiley DC, Mitchison TJ, Stern LJ, et al. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol. 2006;2:197-201.
70. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39:1507-18.
71. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604-11.
72. Chmiel JF, Wessel HU, Targoff IN, Pachman LM. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol. 1995;22:762-5.
73. Targoff IN. Autoantibodies and muscle disease. In: Wotmann RL, editor. Diseases of skeletal muscle. Philadelphia:Lippincott Williams & Wilkins; 2000. p. 267-91.
74. Nishikai M, Ohya K, Kosaka M, Akiya K, Tojo T. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: Evaluation by ELISA using recombinant fusion protein Jo-1 as antigen. Br J Rheumatol. 1998;37:357-61.
75. van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods. 1991;140:181-9.
76. Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: Making detection and interpretation more meaningful. Clin Diagn Lab Immunol. 2002;9:1-7.
77. Lopez-Longo FJ, Rodriguez-Mahou M, Escalona-Monge M, Gonzalez CM, Monteagudo I, Carreno-Perez L. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus. 2003;12:623-9.
78. Ramsden DA, Chen J, Miller FW, Misener V, Bernstein RM, Siminovitch KA, et al. Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response. J Immunol. 1989;143: 2267-72.
79. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 2006;54:2004-9.
80. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, et al. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999;163:130-6.
81. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999;59:3329-32.
82. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70:360-74.
83. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26:129-61.